Recruiting A Study of CDX-1140, a CD40 Agonist, in Combination With Capecitabine and Oxaliplatin (CAPOX) and Keytruda in Subjects With Biliary Tract Carcinoma (BTC) NCT05849480 Conditions Bile Duct Cancer, Bile Duct Diseases, Bile Duct Neoplasms, +8 more Locations National Institutes of Health Clinical Center — Bethesda, Maryland, United States View Trial Details
Completed Single Agent Regorafenib in Refractory Advanced Biliary Cancers NCT02115542 Conditions Bile Duct Diseases, Bile Duct Neoplasms, Biliary Tract Diseases, +15 more Locations H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina, United States VCU Massey Cancer Center — Richmond, Virginia, United States View Trial Details
Active, Not Recruiting Tempus Priority Study: A Pan-tumor Observational Study NCT05179824 Conditions Adnexal Diseases, Bile Duct Diseases, Bile Duct Neoplasms, +113 more Locations UT Southwestern — Dallas, Texas, United States Baylor College of Medicine — Houston, Texas, United States View Trial Details
